DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation of Allogeneic, Injectable Disc Progenitor Cell Therapy for Symptomatic Lumbar Degenerative Disc Disease
DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies for musculoskeletal degeneration, today announced it has gained acceptance from the U.S. Food and Drug Administration (FDA) for the clinical protocols and Chemistry, Manufacturing, and Controls…
DIGITAL THERAPEUTICS STARTUP RESPIREE™ ANNOUNCES INCORPORATION IN US WITH RESIDENCY AT JLABS @ SAN FRANCISCO
Respiree announced today that it has incorporated in the US and will be incubating within Johnson & Johnson Innovation – JLABS @ South San Francisco[1] from February 12, 2024. By expanding footprint within the US, Respiree aims to deepen its relationships and networks…
Clarius and ThinkSono Introduce a New AI-Guided Ultrasound System Enabling Rapid Assessments of DVTs
Clarius Mobile Health, a leading provider of high-definition handheld ultrasound systems, and ThinkSono, a pioneering medical technology company specializing in ultrasound artificial intelligence (AI) guidance solutions, are introducing a new AI-guided ultrasound system in Europe, which will improve the efficiency…
Venus Remedies awarded its first incentive of Rs.7.50 cr. under PLI scheme
Venus Remedies Ltd, one of India’s leading manufacturers of generic drugs, has been awarded its first disbursement of Rs 7.5 crore under the Central government’s Production Linked Incentive (PLI) scheme for the financial year 2022-23, which covers 75% of the…
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLN-619 in relapsed/refractory multiple myeloma. CLN-619 is a potential first-in-class…
The Kinetix Group Introduces Customer-Centric Hospital Approach in New White Paper
The Kinetix Group (TKG) announced the release of its new white paper on optimizing hospital engagement. According to CMS, the hospital market was estimated at $1.4 trillion in 2022, almost a third of our national healthcare expenditures. However, today’s rapidly changing healthcare markets create several…
Therap Services Debuts Secure Document Signing Module (SDS) with Enhanced Digital Security and Efficiency in Streamlining Healthcare Signatures
Therap Services, the national leader in providing HIPAA-compliant electronic documentation solutions to organizations and caregivers in the Long-Term Services and Supports (LTSS), Home and Community-Based Services (HCBS) and broader human services setting, is excited to announce the launch of its…
Philips extends leadership in virtually helium-free MRI with more than 1,000 systems installed, expanding patient access worldwide
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a significant milestone as it expands access to virtually helium-free [1] MRI to more patients in more places, with more than 1,000 systems now installed worldwide. As…
Record-making Partnerships: IntraCare Continues to Strengthen Presence in Arizona as Three More Clinics Sign on in December
IntraCare, a prominent Texas-based MSO, gained record growth in the month of December 2023 upon signing partnership agreements with three medical entities in Arizona. This adds another 16 care practitioners to IntraCare’s provider network. The strategic partnerships with Atembis, LLC; Sun Lake Family Physicians,…
Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach
Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed a memorandum of understanding (MOU) with AstraZeneca China to establish a research and development collaboration at AstraZeneca’s Innovation Campus (iCampus) in Chengdu, China. The signing…
